Targeting the Plasmodium falciparum proteome and organelles for potential antimalarial drug candidates
James Abugri, Joseph Atia Ayariga, Samuel Sunyazi Sunwiale, Cletus Adiyaga Wezena, Julien Agyemang Gyamfi, Michael Adu‐Frimpong, Godfred Agongo, Julius T. Dongdem, Daniel A. Abugri, Bismarck Dinko
Abstract
parasite in humans, which is a worrying situation. Artemisinin combination therapies (ACT) that have so far been the mainstay of malaria have encountered resistance by malaria parasite in South East Asia, which is regarded as a notorious ground zero for the emergence of resistance to antimalarial drugs. This review analyzes a few key druggable targets for the parasite and the potential of specific inhibitors to mitigate the emerging antimalarial drug resistance problem by providing a concise assessment of the essential proteins of the malaria parasite that could serve as targets. Moreover, this work provides a summary of the advances made in malaria parasite biology and the potential to leverage these findings for antimalarial drug production.